Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_2

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

NCT00199901
terminatedphase_1

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

NCT02054104

Clinical Trials (2)

Showing 2 of 2 trials
NCT00199901Phase 2

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Completed
NCT02054104Phase 1

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Terminated

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2